Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?

Eur Respir J. 2015 Mar;45(3):845-8. doi: 10.1183/09031936.00174014. Epub 2014 Nov 27.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Bone Density / drug effects
  • Bone Density / genetics
  • Bone Diseases* / diagnosis
  • Bone Diseases* / drug therapy
  • Bone Diseases* / epidemiology
  • Bone Diseases* / etiology
  • Cystic Fibrosis Transmembrane Conductance Regulator* / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator* / metabolism
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / drug therapy
  • Cystic Fibrosis* / genetics
  • Humans
  • Male
  • Mutation
  • Risk Factors
  • Targeted Gene Repair / methods*

Substances

  • Cystic Fibrosis Transmembrane Conductance Regulator